A phase I study of the safety and immunogenicity of a SARS recombinant DNA plasmid vaccine, VRC-SRSDNA015-00-VP, in healthy adult volunteers
Latest Information Update: 03 Nov 2021
At a glance
- Drugs VRC SRSDNA015 00 VP (Primary) ; Coronavirus vaccine
- Indications Severe acute respiratory syndrome
- Focus Adverse reactions; Pharmacodynamics; Therapeutic Use
- 25 Nov 2008 Results published in Vaccine, reported in a Vical media release.
- 23 Aug 2007 Status changed from in progress to completed.
- 11 Nov 2005 New trial record.